The Keap1/Nrf2 protein complex is now a recognized drug target, several Nrf2 activators are in advanced clinical trials, including in patients with COVID-19, and dimethyl fumarate is used in clinical practice for the treatment of psoriasis (under the brand name Skilarence) and relapsing forms of multiple sclerosis (brand name Tecfidera) (Atanasov et al., 2021; Cuadrado et al., 2019, 2020). Here, NFE2L2 is linked to psoriasis.